Abstract 327P
Background
Sentinel lymph node biopsy (SLNB) has been widely used to assess axillary staging. In clinical practice, it is crucial to define sentinel lymph node (SLN) and determine whether the detected nodes are SLNs during the process of SLNB. It is important to consider whether currently existing consensus on SLNB method which is dual-tracer technique may lead to the excessive and unnecessary removal of negative nodes. In addition, no uniform measurable and objective index has been established to define intra-operation palpable nodes, the excision of which may increase the random detection of SLN. The purpose of this study was to optimize the specific method of SLNB.
Methods
To propose an optimal cut-off value for “radioisotope+bule dye” dual-tracer method, the detailed information of (BC) patients who had no clinical node involvement and underwent SLNB from November 2010 to February 2021 was prospectively collected in the breast surgery department of West China Hospital. We analyzed the site and size, radioactivity, the status of blue dye and the pathological results of each node detected of each patients.
Results
A total of 4985 lymph nodes from 1595 BC patients were identified. Only 11.57% (577/4985) SLNs were defined as pathologically positive, resulting in 88.43% (4408/4985) negative nodes removed excessively. By gradually increasing the threshold of radioisotope count in comparison to the hottest SLN, we found that when elevating the cut-off value from 10% to approximately 60%, 17.3% of lymph nodes were spared removal, among which only 0.88% were missed positive SLNs. Raising the optimal cutoff value of radioisotopes to 60% and exempting palpable nodes at the same time could reduce the number of nodes detected by 30.81% with only 1.75% missed positive SLNs. Additionally, multivariate analysis in our study showed that larger tumor size and higher clinical N stage was significantly positively associated with SLN metastasis.
Conclusions
Raising the optimal cut-off value of radioisotope to 60% and exempting palpable nodes may be considered as a potential alternative method to avoid removing excessive negative nodes in SLNB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q. Lv.
Funding
West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
233P - Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Presenter: Marianela Bringas Beranek
Session: Poster session 02
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02
236TiP - Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Presenter: Shingo Kitagawa
Session: Poster session 02
247P - KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
Presenter: Linxiaoxi Ma
Session: Poster session 02
248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Presenter: Francesca Ligorio
Session: Poster session 02
250P - The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer
Presenter: Luke Steventon
Session: Poster session 02
251P - Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Presenter: Jose Angel García-Sáenz
Session: Poster session 02